Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

0.3098 +0.0098 (+3.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 642,919
Open 0.3200
Bid (Size) 0.3040 (10)
Ask (Size) 0.3200 (5)
Prev. Close 0.3000
Today's Range 0.3027 - 0.3275
52wk Range 0.2223 - 2.535
Shares Outstanding 61,974,755
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga

Performance

YTD
-57.2%
-57.2%
1 Month
+29.6%
+29.6%
3 Month
-26.4%
-26.4%
6 Month
-58.7%
-58.7%
1 Year
-81.4%
-81.4%

More News

Read More
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
These stocks are moving in today's pre-market session
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Philanthropic Donor Funds Cognition Therapeutics’ Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Reports Financial Results for the First Quarter 2025 and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Earnings Scheduled For March 20, 2025
Via Benzinga
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Life Sciences Investor Forum Agenda Announced for March 13th
From Virtual Investor Conferences
Via GlobeNewswire
Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)
From Cognition Therapeutics, Inc.
Via GlobeNewswire
Cognition Therapeutics Presents Phase 2 Results For Drug To Fight DLB At International Conference
Via News Direct
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC
From Cognition Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Cognition Therapeutics, Inc. - Common Stock publicly traded?
Yes, Cognition Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Cognition Therapeutics, Inc. - Common Stock trade on?
Cognition Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cognition Therapeutics, Inc. - Common Stock?
The ticker symbol for Cognition Therapeutics, Inc. - Common Stock is CGTX on the Nasdaq Stock Market
What is the current price of Cognition Therapeutics, Inc. - Common Stock?
The current price of Cognition Therapeutics, Inc. - Common Stock is 0.3098
When was Cognition Therapeutics, Inc. - Common Stock last traded?
The last trade of Cognition Therapeutics, Inc. - Common Stock was at 06/30/25 04:00 PM ET
What is the market capitalization of Cognition Therapeutics, Inc. - Common Stock?
The market capitalization of Cognition Therapeutics, Inc. - Common Stock is 19.20M
How many shares of Cognition Therapeutics, Inc. - Common Stock are outstanding?
Cognition Therapeutics, Inc. - Common Stock has 19M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.